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ttp://dx.doi.org/10.1016/j.ajpath.2016.01.023Angiotensin-converting enzyme (ACE)-2 is the primary enzyme of the vasoprotective axis of the renin
angiotensin system that regulates the classic renin angiotensin system axis. We aimed to determine
whether local retinal overexpression of adenoassociated virus (AAV)eACE2 prevents or reverses diabetic
retinopathy. Green ﬂuorescent protein (GFP)echimeric mice were generated to distinguish resident
(retinal) from inﬁltrating bone marrowederived inﬂammatory cells and were made diabetic using
streptozotocin injections. Retinal digestion using trypsin was performed and acellular capillaries
enumerated. Capillary occlusion by GFPþ cells was used to measure leukostasis. Overexpression of ACE2
prevented (prevention cohort: untreated diabetic, 11.3  1.4; ACE2 diabetic, 6.4  0.9 per mm2) and
partially reversed (reversal cohort: untreated diabetic, 15.7  1.9; ACE2 diabetic, 6.5  1.2 per mm2) the
diabetes-associated increase of acellular capillaries and the increase of inﬁltrating inﬂammatory cells into
the retina (F4/80þ) (prevention cohort: untreated diabetic, 24.2  6.7; ACE2 diabetic, 2.5  1.6 per
mm2; reversal cohort: untreated diabetic, 56.8  5.2; ACE2 diabetic, 5.6  2.3 per mm2). In both study
cohorts, intracapillary bone marrowederived cells, indicative of leukostasis, were only observed in
diabetic animals receiving control AAV injections. These results indicate that diabetic retinopathy,
and possibly other diabetic microvascular complications, can be prevented and reversed by locally
restoring the balance between the classic and vasoprotective renin angiotensin system. (Am J Pathol
2016, 186: 1688e1700; http://dx.doi.org/10.1016/j.ajpath.2016.01.023)Supported by NIH grants EY-07739, EY-12601, DK-090730-02,
EY-018358, EY-021626, HL-110170 (all to M.B.G.), and EY-021752
(Q.L.). Core facilities were supported by NIH National Eye Institute grant
P30 EY-02172 and Research to Prevent Blindness.
Disclosures: None declared.Microvascular complications of diabetes constitute a number
of painful and debilitating conditions. Previously, we found
that the bone marrow is susceptible to diabetic neuropathy,1,2
which leads to denervation of stromal cells and altered
secretion of growth factors and cytokines that ultimately
shifts hematopoiesis toward a disproportionate increase of
proinﬂammatory monocytes.3,4 Consequently, monocytes are
increased in the circulation and subsequently in tissues sub-
ject to diabetic complications, including retina, kidney, and
brain.5 Diabetic retinopathy (DR), the most common diabetic
microvascular complication and the leading cause of blind-
ness in working adults, is characterized by inﬂammation,
leukostasis, and microangiopathy. Current treatment options
are symptomatic and suboptimal, and prevention strategiesstigative Pathology. Published by Elsevier Incare limited to aggressive regulation of blood pressure, lipids,
and glucose.6 However, studies suggest that manipulation of
the systemic and local retinal renin angiotensin system (RAS)
may offer new and powerful therapeutic options.
The levels of almost all proinﬂammatory, classic RAS
components [prorenin, renin, angiotensinogen, angiotensin-
converting enzyme (ACE)-1, angiotensin II (Ang II), and
the Ang II type 1 receptor (AGTR1)] are signiﬁcantly. All rights reserved.
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Figure 1 Experimental approach. A: Prevention cohort. B: Reversal
cohort. C: Maps of the adenoassociated virus (AAV) vectors expressing the
human ACE2 gene (hACE2) and the control (Con) vector expressing a reverse
sequence for green ﬂuorescent protein (GFP). ACE2, angiotensin-converting
enzyme; CBA, chicken b-actin promoter; ITR, inverted terminal repeat; STZ,
streptozotocin; Veh, vehicle. Adapted from Verma et al.10
ACE2 Overexpression Reverses DRelevated in ocular tissues of diabetic patients7,8 and
animals.9,10 Accordingly, systemically administered ACE1
inhibitors and AGTR1 antagonists attenuate retinal micro-
vascular disease in diabetic rodents by decreasing vascular
hyperpermeability, acellular capillaries, and the expression
of angiogenic factors, such as vascular endothelial growth
factor.9,11 Despite the clear success of systemic RAS
blockade in diabetic rodents, systemic suppression in
humans has led to only marginal improvement. AGTR1
blockade decreased the incidence of DR in individuals with
type 1 diabetes and improved mild and moderate DR in
those with type 2 diabetes. However, AGTR1 blockade did
not inﬂuence DR progression or DR at the more advanced
stages once ischemic changes were present.12,13 The most
widely proposed explanation for this shortcoming is that the
blood-retinal barrier limits access of therapeutic concentra-
tions of systemically administered pharmaceuticals, such
that suppression of the classic RAS in ocular tissues fails to
occur.10 From these data, the notion has emerged that
restoring the balance between the classic RAS and its
endogenous counterbalance, the vasoprotective RAS, rep-
resents a viable strategy for controlling DR in humans. The
crucial enzyme in this axis is ACE2, which converts the
vasoconstrictive and proinﬂammatory peptide, Ang II, into
the vasodilatory and anti-inﬂammatory peptide, angiotensin-
(1-7) [Ang(1-7)], which mediates its effects primarily
through the receptor Mas.14 Importantly, ACE1 inhibitors
do not block the effects of ACE2.15
Thus, restoring the local retinal RAS balance, by bolstering
the vasoprotective RAS, may diminish oxidative stress and
chemokine production, decreasing inﬂammatory cell inﬁl-
tration and preventing retinal vasodegeneration, the key his-
tologic characteristic of DR. In this study, we asked whether
local retinal overexpression of ACE2 could prevent or reverse
the histologic features of DR in a mouse model of type
1 diabetes and whether a decrease in resident and bone
marrowederived inﬂammatory cells in the retina would occur.
Materials and Methods
Experimental Approach
The experimental paradigm is shown in Figure 1A for the
prevention cohort and in Figure 1B for the reversal cohort.
Brieﬂy, the prevention cohort consisted of C57BL/6 mice that
underwent bone marrow transplantation with hematopoietic
progenitor cells from GFPþ mice. These GFPþ-chimeric
mice received an intravitreal injection with adenoassociated
virus (AAV)eACE2 or AAV-reverse-GFP (control vector)
and were subsequently made diabetic with streptozotocin
(Figure 1A). This approach allowed us to test the hypothesis
that retinal overexpression of ACE2 improves the diabetic
phenotype of the retina, characterized by increased acellular
capillaries and increased inﬂammatory cell expression. The
reversal cohort tested the ability of retinal overexpression of
ACE2 to reverse preexisting disease by administeringThe American Journal of Pathology - ajp.amjpathol.orgstreptozotocin 6 months before AAV injections (Figure 1B).
Both studies used the same end points. The AAV constructs
are shown in Figure 1C.
Generation of GFP-Chimeric Mice
We used two timeline sequences that enabled us to evaluate
a prevention role (Figure 1A) and a reversal role (Figure 1B)
for ACE2 overexpression. To determine whether retinal
overexpression of ACE2 prevents the inﬂammatory bone
marrow cell inﬂux into the diabetic retina, C57BL/6-GFP-
chimeric mice were generated. Male C57BL/6 mice (nZ 7
per group), which were obtained commercially from The
Jackson Laboratory (Bar Harbor, ME), were housed ﬁve per
cage with unrestricted access to food and water with a 12:12
light:dark cycle. All procedures that involved mice were
performed in accordance with the guidelines of the1689
Dominguez et alUniversity of Florida Institutional Animal Care and Use
Committee. GFP-chimeric mice were generated as previ-
ously described.16 Brieﬂy, bone marrow was harvested from
the femurs of GFPþ transgenic (homozygous) mice. From
the total bone marrow cells, the c-KitþSca-1þ hematopoietic
stem cells were puriﬁed by FACS using anti-GFP, antie
c-Kit, and antieSca-1 antibodies (BD Biosciences, San Jose,
CA). Cells (>5000) and were then injected into lethally
irradiated adult C57BL/6 mice via retro-orbital sinus.
Streptozotocin-induced diabetes was induced by i.p.
injection of streptozotocin (50 mg/kg in 100 mmol/L
sodium citrate, adjusted to pH 4.5) for 5 consecutive days.
Control mice were injected with sodium citrate (vehicle)
alone. Diabetes was veriﬁed 2 weeks later by measuring
blood glucose (deﬁned as >250 mg/dL) using a glucometer
(Glucometer Elite XL; Bayer Corp, Elkhart, IN) according to
the manufacturer’s instructions. Glycated hemoglobin was
measured at the end of the study, and animals were consid-
ered diabetic if the glycated hemoglobin level was >7.5%.
AAV Construct
Maps of the AAV vectors used in this study are shown in
Figure 1C. A secreted form of human ACE2 lacking the
membrane domain, which has been previously character-
ized,17 was cloned into an AAV vector under the control of
the chicken b-actin promoter and packaged into serotype 2
viral particles, as previously described.10 Serotype 2 typi-
cally infects ganglion cells in the ganglion cell layer and
horizontal and amacrine cells in the inner nuclear layer.10
Previously, we found that this secreted, truncated ACE2
had approximately fourfold higher activity in media from
transfected cells and approximately eightfold higher activity
in serum collected from systemically injected neonatal rats
when compared with the membrane-bound enzyme.17 This
viral vector, delivered by intravitreal injection, resulted in a
greater than twofold increase of ACE2 activity with a
approximately 50% decrease of Ang II and a 2.3-fold
increase of Ang(1-7) levels.10 The control vector contained
a GFP coding region in reverse sequence.
ACE2 Activity Assay
HEK293 cells were infected with ACE2-AAV2 triple
mutant Y-F (reference K2742) at 5000 multiplicity of
infection for 72 hours. Cells were washed in phosphate-
buffered saline and harvested in ACE2 activity assay buffer
(buffer has 1 mmol/L Tris-HCl, pH 7.5, 5 mmol/L NaCl,
and 1 mmol/L ZnCl2). Cells were sonicated for 20 seconds
on ice and centrifuged at 6010  g for 20 minutes. The
supernatant was subjected to protein estimation and used for
ACE2 activity assay. The ACE2 activity assay was per-
formed using 50 mg of protein in black 96-well opaque
plates with 50 mmol/L ACE2-speciﬁc ﬂuorogenic peptide
substrate VI (R&D Systems, Minneapolis, MN) in a ﬁnal
volume of 100 mL per well reaction mixture. The enzymatic1690activity was recorded in a SpectraMax M3 ﬂuorescence
microplate reader (Molecular Devices, LLC, Sunnyvale,
CA) for 1 hour with 90-second intervals at excitation 340
nm and emission 400 nm.
Intravitreal AAV Injections
Eyes were dilated by topical administration of 1% atropine
sulfate ophthalmic solution (Bausch & Lomb, Tampa, FL)
and 2.5% phenylephrine hydrochloride ophthalmic solution
(Akorn, Vernon Hills, IL). Animals were then anesthetized
by 72 mg/kg of i.p. ketamine and 4 mg/kg of xylazine
injection. Intravitreal injection was made through sclera/
choroid into the vitreous cavity using a 33-gauge beveled
sharp needle (Hamilton Company, Reno, NV). One micro-
liter of AAV (approximately 109 vg) was injected for each
mouse eye. In the prevention cohort (Figure 1A), to ensure
sufﬁcient therapeutic expression of ACE2 before the onset
of diabetes, AAV was injected intravitreally 2 weeks before
induction of diabetes.
ACE2 Activity Assay in Mouse Retina Injected with
ACE2-AAV2 Viral Vector
To conﬁrm viral expression of ACE2, 1 mL of viral vector
(or phosphate-buffered saline as control) was injected into
the vitreous of C57BL/6 mice. Mice were euthanized 3
weeks after injection, and retinal protein was extracted for
ACE2 activity assay as described above.
Trypsin Digest Preparation of Retinal Vasculature
Retinal vasculature was prepared using the method
described by Kuwabara and Cogan18 with minor modiﬁca-
tions. Retinas were scanned by an Aperio CS slide scanning
system with Spectrum Plus information management system
(Aperio Technologies, Inc., Vista, CA). Ten to 15 random,
nonoverlapping ﬁelds of 100,000 mm2 from each retina were
imaged. Acellular capillaries >50 mm in length were
counted from images for each retina and expressed as
number of acellular vessels per square millimeter.
Immunohistochemistry of Cryosections
Sections were prepared as previously described.19 Primary
antibodies were administered at 1:200 and secondary anti-
bodies at 1:400. Antibodies included glial ﬁbrillary acidic
protein (GFAP) (ab53554; Abcam, Cambridge, England)
plus secondary (ab150132; Abcam), F4/80 (ab6640; Abcam)
plus secondary (Abcam; ab150160), and isolectin-B4 conju-
gated to DyLight 594 (DL-1207; Vector Laboratories, Bur-
lingame, CA). Primary antibodies were allowed to incubate
overnight at 4C, whereas secondary antibodies incubated for
1 hour at room temperature. DAPI (Life Technologies,
Carlsbad, CA) was applied at 300 nmol/L for 5 minutes at
room temperature. Slides were then coverslipped withajp.amjpathol.org - The American Journal of Pathology
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Figure 2 Angiotensin-converting enzyme
(ACE)-2 overexpression decreases retinal acellular
capillaries. A: Prevention cohort; representative
images of retinal vasculature after trypsin diges-
tion showing acellular capillaries (arrowheads) in
green ﬂuorescent protein (GFP)-chimeric, strep-
tozotocin (STZ)ediabetic, and vehicle (Veh)e
control (Con) mouse retinas. B: Prevention cohort;
quantiﬁcation of retinal acellular capillaries.
C: Reversal cohort; representative images of
retinal vasculature after trypsin digestion showing
acellular capillaries (arrowheads) in GFP-chimeric,
STZ-diabetic, and Veh-Con mouse retinas.
D: Reversal cohort; quantiﬁcation of retinal
acellular capillaries. Data are expressed as
means  SEM. *P < 0.05 versus STZ-Con;
yP < 0.05 versus respective nondiabetic control.
Scale bar Z 50 mm.
ACE2 Overexpression Reverses DRantifade medium (Vectashield; Vector Laboratories), and
images were taken with a Hamamatsu digital camera (model
C11440; Hamamatsu City, Shizuoka, Japan) through an
inverted microscope (Zeiss Axio Imager.D2; Zeiss, Oberko-
chen, Germany) and photographed at 20 magniﬁcation.
Positive ﬂuorescence was quantiﬁed from three retinal sec-
tions per animal by manual counting of cells or by Aperio’s
Positive Pixel Count algorithm (Aperio Technologies, Inc.,
Vista, CA). Brieﬂy, the ImageScope program (Aperio) uses
the Positive Pixel Count algorithm to quantify positive
staining based on a custom range of hues, saturation, and
intensity for the ﬂuorophore of interest. Negative controls for
all targets were analyzed to ensure that the algorithm detected
minimal false-positive results and autoﬂuorescence.
Localization of Bone MarroweDerived Cells within
Retinal Vasculature
GSL I - isolectin B4, conjugated with Alexa-Fluor 594
(Vector Laboratories), was used in retinal cross sections to
identify the vasculature. Leukostasis was assessed by
enumeration of intraluminal leukocytes (bone marrow
derived, GFPþ) as nucleated cells devoid of dendritic pro-
cesses. Three retinal cross sections from ﬁve animals per
group were analyzed.The American Journal of Pathology - ajp.amjpathol.orgData Analysis
All data were analyzed for outliers before treatment com-
parisons. Comparisons between the groups were assessed
using a one-way analysis of variance followed by the Tukey
post-hoc test. P < 0.05 was considered signiﬁcant.
Results
Overexpression of Vasoprotective RAS Reduces the
Number of Acellular Capillaries
Streptozotocin-induced diabetes resulted in a signiﬁcant
decrease in body mass and a signiﬁcant increase in glycated
hemoglobin, as expected in streptozotocin mice in both
cohorts (Supplemental Tables S1 and S2). The expression of
the AAV-ACE2 virus was conﬁrmed by increases in ACE2
activity in vitro after infection of HEK293 cells (Supplemental
Figure S1A) and in vivo after injection of AAV-ACE 2 into
the vitreous of wild-type mice (Supplemental Figure S1, B
and C). Six months of hyperglycemia induced signiﬁcant
increases of retinal acellular capillaries in the untreated diabetic
animals (streptozotocin-control group). Despite profound sys-
temic hyperglycemia, the increase in acellular capillaries was
prevented by intravitreal injection of AAV-ACE2 2 weeks1691
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Figure 3 Angiotensin-converting enzyme
(ACE)-2 overexpression reverses bone marrow cell
inﬁltration. A: Reversal cohort; representative
immunoﬂuorescence images showing green ﬂuo-
rescent proteinepositive (GFPþ) cells (arrowheads)
in GFP-chimeric, streptozotocin (STZ)ediabetic, and
vehicle (Veh)econtrol (Con) mouse retinas. BeF:
Reversal cohort; quantiﬁcation of GFPþ cells per
square millimeter in the discrete retinal layers.
B: Total cells in all layers. C: Ganglion cell layer.
D: Inner plexiform layer. E: Inner nuclear layer.
F: Outer plexiform layer. Data are expressed as
means  SEM. *P < 0.05 versus STZ-Con. Scale
barZ 100 mm. GCL, ganglion cell layer; INL, inner
nuclear layer; IPL, inner plexiform layer; ND, no cells
detected; ONL, outer nuclear layer.
Dominguez et albefore streptozotocin administration (Figure 2, A and B).
Similarly, 12 months of hyperglycemia resulted in increased
acellular capillaries in the untreated diabetic group (streptozo-
tocin-control group) and was partially reversed in the mice
receiving AAV-ACE2 six months after streptozotocin admin-
istration (Figure 2, C and D).
Bone Marrow Cells Preferentially Localize to Inner
Retinal Layers
Use of GFPþ-chimeric mice allowed for the identiﬁcation of
cells originating from the bone marrow. In the mice that
received intravitreal injections before the induction of dia-
betes (prevention cohort), the total number of retinal GFPþ
cells was not different between the experimental groups1692(Figure 3). Similarly, in this cohort, the number of GFPþ
cells detected in individual retinal layers was not different
between the experimental groups. In contrast, in mice
receiving intravitreal injections 6 months after diabetes
onset (reversal cohort), the total number of retinal GFPþ
cells was highest in the untreated diabetic group (strepto-
zotocin-control group) and was reduced with administration
of AAV-ACE2 (Figure 3). In both the prevention cohort and
the reversal cohort, inﬁltrating cells appeared predominantly
along the anterior aspect of the ganglion cell layer and in the
inner plexiform layer. In the prevention cohort, few GFPþ
cells, irrespective of treatment group, were observed in the
inner nuclear layer or outer plexiform layer.
Neither cohort had GFPþ cells posterior to the outer
plexiform layer. Another consistent observation in all groups,ajp.amjpathol.org - The American Journal of Pathology
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Figure 4 Angiotensin-converting enzyme
(ACE)-2 overexpression prevents diabetes-induced
increase of glial ﬁbrillary acidic protein (GFAP)
expression in the prevention study. A: Prevention
cohort; representative immunoﬂuorescence images
showing GFAP-positive astrocytes (red). B: Preven-
tion cohort; percent area of GFAP staining in green
ﬂuorescent protein (GFP)echimeric, streptozotocin
(STZ)ediabetic, and vehicle (Veh)econtrol (Con)
mouse retinas. C: Reversal cohort; representative
immunoﬂuorescence images showing GFAP-positive
astrocytes (red). D: Reversal cohort; percent area of
GFAP staining in GFP-chimeric, STZ-diabetic, and
Veh-Con mouse retinas. Data are expressed as
percent area  SEM. *P < 0.05 versus STZ-Con.
Scale bar Z 100 mm. GCL, ganglion cell layer;
INL, inner nuclear layer; ONL, outer nuclear layer.
ACE2 Overexpression Reverses DRin both the prevention and reversal cohorts, was the asym-
metrical distribution of GFPþ cells, from section to section,
presumably reﬂecting localized regions of disease.20
GFAP Immunohistochemistry in ACE2-Overexpressing
Retinas
GFAP is an intermediate ﬁlament and marker of astrocytes
that is up-regulated during high glucose and neuronal
damage.21,22 It is also interpreted as an indication of stress
and damage in astrocytes.22 In the prevention cohort, dia-
betes was associated with elevated GFAP immunoreactivity
compared with nondiabetic controls, and retinal over-
expression of ACE2 in diabetic animals prevented this in-
crease (Figure 4, A and B). In the reversal cohort, however,
GFAP immunoreactivity in the diabetic animals was not
different from the other groups (Figure 4, C and D). GFAP
immunoﬂuorescence was higher in the reversal cohort by
approximately threefold compared with the prevention
cohort, which is consistent with the observed age-associated
increase in GFAP in normal, nondiabetic C57 mice.23
F4/80 Immunohistochemistry in ACE2-Overexpressing
Retinas
F4/80 is a well-known and widely used marker of murine
macrophage populations.24 In both the prevention and the
reversal studies, F4/80þ cells were located within theThe American Journal of Pathology - ajp.amjpathol.orgganglion cell layer of mice and were predominantly
ameboid or elongated in appearance. Most F4/80þ cells
were also GFPþ and existed in clusters. This ﬁnding is not
unexpected and is reminiscent of human disease because
microglia accumulate around regions of vascular damage in
individuals with DR,25 and these vascular lesions are
nonuniform in distribution.20 In both the prevention and the
reversal studies, F4/80þ cells in the streptozotocin-control
group were approximately threefold to fourfold higher
than nondiabetic controls (Figure 5). In addition, in both
cohorts, retinas from ACE2-treated diabetic animals revealed
decreased F4/80þ cells, comparable to nondiabetic control
levels. In the prevention cohort, the proportion of these cells
that were double-labeled F4/80þGFPþ was approximately
50%, in all groups except streptozotocin-ACE2, which was
approximately 25%. This ﬁnding represents the proportion
of F4/80þ cells that are bone marrow derived in contrast
to resident. In the reversal cohort, in all groups except
streptozotocin-ACE2, nearly all F4/80þ cells were also
GFPþ. In streptozotocin-ACE2, approximately 50% were
double labeled F4/80þGFPþ.
F4/80þ cells in the inner plexiform layer and outer
plexiform layer of both diabetic and nondiabetic animals, in
both the prevention and reversal studies, possessed a regular
distribution and high degree of dendritic processes. Thus,
the increased numbers of F4/80þ cells in the streptozotocin-
control group likely reﬂects perivascular macrophages at the
ganglion cell layer (Figure 5).1693
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C Figure 5 Angiotensin-converting enzyme
(ACE)-2 overexpression prevents diabetes-induced
increase of macrophage/microglial cells. A: Pre-
vention cohort; representative immunoﬂuorescence
images of F4/80-positive (red arrowheads) and
F4/80egreen ﬂuorescent protein (GFP)epositive
(yellow arrowheads) cells in GFP-chimeric, strep-
tozotocin (STZ)ediabetic, and vehicle (Veh)e
control (Con) mouse retinas. B: Prevention cohort;
quantiﬁcation of F4/80-positive cells per square
millimeter. C: Prevention cohort; quantiﬁcation of
F4/80-GFPepositive cells per square millimeter.
D: Reversal cohort; representative immunoﬂuores-
cence images of F4/80-positive (red arrowheads)
and F4/80-GFPepositive (yellow arrowheads) cells
in GFP-chimeric, STZ-diabetic, and Veh-Con mouse
retinas. E: Reversal cohort; quantiﬁcation of F4/80-
positive cells per square millimeter. F: Reversal
cohort; quantiﬁcation of F4/80-GFPepositive
cells per square millimeter. Data are expressed as
means  SEM. *P < 0.05 versus STZ-Con. Scale
barZ 100 mm. GCL, ganglion cell layer; INL, inner
nuclear layer; ONL, outer nuclear layer.
Dominguez et alIntracapillary Bone Marrow Cells in Diabetic Mice
Leukostasis occurs as a result of aberrant leukocyte-
endothelial cell adhesion and is a major factor in the patho-
genesis of DR, contributing to capillary nonperfusion and
ischemia.26e28 In both the prevention and reversal studies,
bone marrowederived cells were only observed within the
vascular lumen in the streptozotocin-control groups (Figure 6)
and not in any of the other groups.
Discussion
There are several key ﬁndings from this study. First, local
retinal overexpression of ACE2 prevented (Figure 2, A and B)
and partially reversed (Figure 2, C and D) the diabetes-
associated increase of acellular capillaries. We are not
aware of another study that has found a therapy capable of1694reversing this form of retinal disease, particularly in the pres-
ence of persistent untreated hyperglycemia. Second, ACE2
overexpression prevented (Figure 5, AeC) and reversed
(Figure 5, DeF) the diabetes-induced increase of macro-
phages/microglia and prevented the diabetes-associated
increase of macroglia immunoreactivity as detected by
GFAP (Figure 4, A and B). This ﬁnding supports the literature
reporting that Ang II mediates increased intercellular adhesion
molecule (ICAM)-1 expression, chemokine production, and
subsequent macrophage inﬁltration.29,30 Third, local retinal
overexpression of ACE2 prevented (Figure 6, A and B) and
reversed (Figure 6, C and D) the occurrence of intravascular
bone marrowederived cells, an index of leukostasis. The
signiﬁcance of leukostasis is that it promotes acellular capil-
lary formation and localized ischemia.26e28
Our studies suggest that local retinal overexpression
of the vasoprotective RAS attenuates the release ofajp.amjpathol.org - The American Journal of Pathology
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Figure 6 Angiotensin-converting enzyme (ACE)-2 overexpression decreases diabetes-induced increase of intracapillary bone marrow cells. A: Prevention
cohort; representative image of a bone marrowederived cell (arrowhead) located within the lumen of a retinal capillary. B: Prevention cohort; quantiﬁcation
of green ﬂuorescent proteinepositive (GFPþ) cells per square millimeter, as observed from retinal cross sections. C: Reversal cohort; representative image of a
bone marrowederived cell (arrowhead) located within the lumen of a retinal capillary. D: Reversal cohort; quantiﬁcation of GFPþ cells per square millimeter,
as observed from retinal cross sections. Data are expressed as means  SEM. *P < 0.05 versus streptozotocin (STZ)econtrol (Con). Scale bar Z 50 mm.
GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ND, not detected; ONL, outer nuclear layer.
ACE2 Overexpression Reverses DRproinﬂammatory mediators from the retina because fewer
circulating bone marrowederived inﬂammatory cells were
recruited to the retina and fewer intracapillary bone marrow
cells were occluding capillaries. The decline of retinal
intracapillary bone marrow cells is the presumed explana-
tion for our ﬁnding that ACE2 overexpression prevented
and reversed retinal vascular disease, as measured by acel-
lular capillaries. The present study expands on our previous
work,10 which used two models of DR: an accelerated
model in mice (streptozotocin-induced diabetes in eNOS/
mice) and a long-term model (14 months) in rats (strepto-
zotocin in Sprague-Dawley rats). The primary advancements
provided by the present study include the assessment of bone
marrowederived cells in the retina and the partial reversal of
DR after a prolonged period of untreated diabetes.
Retinal Overexpression of ACE2 May Attenuate
Vasodegeneration by Suppressing Classic RAS
Signaling
The mechanisms that lead to the vasodegenerative phase of
DR (eg, pericyte and vascular endothelial cell death) are not
entirely known. However, there are multiple RAS-mediated
mechanisms that could contribute. Numerous studies have
found that AGTR1 activation leads to increased NADPH
oxidase activity and increased production of reactive
oxygen species, which directly damage the vasculature. In
addition, the diabetes-associated increase of leukostasis,
which directly contributes to capillary nonperfusion in
rodents,26e28 is mediated largely by the increase of Ang II
and the subsequent increase of NADPH oxidase and O2
.31
For example, in nondiabetic animals,31,32 intravitreal admin-
istration of Ang II increases leukostasis to comparable levels
seen in diabetes. Ang II also sensitizes endothelial cells to
tumor necrosis factor (TNF)-aeinduced ICAM-1 expression
and monocyte adhesion, which implies that Ang II is
an autocrine regulator of endothelial cell inﬂammatory
responses.33 Accordingly, retinal leukostasis and the up-
regulation of adhesion molecules (eg, ICAM and vascular
cell adhesion molecule) are decreased with the blockade ofThe American Journal of Pathology - ajp.amjpathol.orgclassic RAS.11,34 Our studies suggest that local retinal over-
expression of ACE2 activity10 provides several mechanisms
to counter the diabetes-associated increase of classic RAS
signaling and the subsequent detrimental effects on the
vasculature. ACE2 has a powerful role in opposing the classic
RAS in that it converts the proinﬂammatory/vasoconstrictive
Ang II into the anti-inﬂammatory/vasodilatory Ang(1-7).35,36
Thus, ACE2 effectively mitigates the primary vasoconstrictive/
proinﬂammatory aspects of the classic RAS, while increasing
the primary anti-inﬂammatory/vasodilatory features.
Consistent with the literature,26e28 the increase of intra-
capillary GFPþ bone marrowederived cells in streptozotocin-
control (Figure 6) corresponds with the increase of acellular
capillaries (Figure 2). Our ﬁnding that bone marrowederived
cells were only observable within the capillary lumen in the
streptozotocin-control groups is consistent with the idea
that the classic RAS is critically involved in this vascular
abnormality. In fact, retinal leukostasis and the up-regulation
of adhesion molecules are decreased with classic RAS
blockade,11 and the absence of intravascular bone marrow
cells in the present streptozotocin-ACE2 mice is a tenable
mechanistic explanation for the decrease of acellular capil-
laries. Speciﬁcally, in our model, ACE2 metabolism of Ang II
would be expected to counter the putative Ang IIemediated
increase of chemokine ligand (CCL)-2 and ICAM at the retinal
vascular endothelium,29,30 thus decreasing recruitment and
adhesion of inﬂammatory cells29 to the retinal vasculature
(Figure 7). This model is consistent with the notion that,
although diabetes induces notable changes in circulating
chemokines, as well as their receptor expression on leuko-
cytes, the major diabetes-associated defect originates at the
vascular endothelium and is a prerequisite for the development
of leukostasis37 because decreasing leukocyte adhesion delays
development of DR.38 The primary limitation of the analysis
being performed in cross sections, rather than in retinal ﬂat
mounts, is that the vascular density is underrepresented, thus
underrepresenting the frequency of events and rendering
quantiﬁcation difﬁcult to compare with published literature
(between 0.2 and 4 leukocytes per square millimeter in dia-
betic retinal ﬂat mounts).31,321695
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Figure 7 Model for diabetic retinal leukostasis in the present study. In
the untreated diabetic eye (bottom image), the relative expression of the
vasodeleterious axis exceeds the vasoprotective axis, which up-regulates
proinﬂammatory factors in the retina and adhesion molecules in the
retinal circulation. This promotes inﬁltration and adhesion of leukocytes,
which contributes to diabetic retinopathy. Our model proposes that local
retinal up-regulation of the vasoprotective axis in diabetic animals (top
image), indicated by adenoassociated virus (AAV)eangiotensin-converting
enzyme (ACE)-2, will provide protective and reparative mediators on a long-
term basis, restoring the balance between the two axes. This will inhibit the
up-regulation of proinﬂammatory factors in the retina and adhesion
molecules in the retinal circulation, which prevent inﬁltration and adhesion
of leukocytes, preventing characteristics of diabetic retinopathy, despite
systemic hyperglycemia, and an abundance of circulating leukocytes.
Ang II, angiotensin II; CCL2, chemokine ligand 2; ICAM, intercellular
adhesion molecule.
Dominguez et alRetinal Overexpression of ACE2 May Suppress
Proinﬂammatory Signals from Local and Inﬁltrating
Immune Cells
The structural integrity of the blood-retinal barrier is crucial
for retinal homeostasis in part to prevent circulating cyto-
kines from inﬂuencing local retinal cell function. Glia and
pericytes are important mediators of blood-retinal barrier
integrity. Furthermore, the activation and dysfunction
of astrocytes (macroglial cells) are key contributors to
its breakdown and subsequent increased permeability in
DR.39,40 Elevated GFAP expression is interpreted as an
indication of stress and neurodegeneration or gliosis22 and is
associated with oxidative stress and increased production of
proinﬂammatory molecules (TNF-a, IL-1b, and inducible
nitric oxide synthase) in retinal astrocytes.21 Our ﬁndings
are consistent with the literature on diabetic mouse models
in that untreated diabetes was associated with elevated retinal
GFAP immunoreactivity compared with nondiabetic controls
in the prevention cohort (Figure 4, A and B). Retinal over-
expression of ACE2 in diabetic animals prevented this in-
crease, presumably functioning to improve blood-retinal
barrier function. The most likely explanation for this bene-
ﬁcial effect of ACE2 overexpression is the collective effect
at AGTR1 on astrocytes41 and other immune cells of the1696retina. For example, decreased signaling through AGTR1
decreases GFAPþ astrocytes,42 which can be accomplished
by increased metabolism of Ang II and generation of
Ang(1-7).43 Furthermore, there is increasing evidence to
suggest that glial cells act as an intermediary between
oxidative stress and neuroinﬂammation.44 Oxidative damage
to glial cells produces excessive proinﬂammatory cytokines,
which activates neuronal membrane receptors to induce
inﬂammatory pathways, resulting in neuroinﬂammation.45
Thus, by preventing gliosis, overexpression of ACE2 would
be expected to mitigate the diabetes-associated increase of
proinﬂammatory molecules, as well as the disruption of the
blood-retinal barrier. This effect may be particularly important
to suppress microglial hyperactivation and the putative
feed-forward increase of inﬂammation and oxidative stress.
In the reversal study, GFAP immunoreactivity in the
untreated diabetic animals was not different from the other
groups (Figure 4, C and D). Moreover, GFAP immunoﬂu-
orescence was higher in the reversal study by approximately
threefold compared with the prevention cohort. A possible
explanation for this is that GFAP expression increases with
aging in C57 mice23; animals in the reversal study were
approximately 50% older than animals in the prevention
study. However, there appears to be a species difference
(mice versus primates and rats) regarding GFAP immuno-
reactivity in Müller cells during diabetes, which is consis-
tent with our present ﬁndings. GFAP immunoreactivity
in Müller cells increases in both primates and rats after
a relatively short duration of diabetes. Asnaghi et al46
assessed GFAP immunoreactivity in rats but also in mice.
Diabetic rats had increased Müller cell immunoreactivity for
GFAP. However, at 10 or 24 weeks of diabetes, GFAP
staining in diabetic mice was typical of astrocytes and
appeared unaltered, and there was no indication of Müller
cell reactivity. Barber et al47 found that Ins2 Atika mice had
microglial activation but no increase in GFAP expression by
Müller cells. Similarly, in mice with alloxan-induced dia-
betes, no glial reaction, as assessed by GFAP labeling, could
be detected 1 or 3 months after induction.48 Finally, Feit-
Leichman et al49 revealed a transient increase in GFAP
(1 to 2 months) in astrocytes in the ganglion cell layer but
not in Müller cells of streptozotocin-diabetic mice. In com-
plete agreement with our ﬁndings, this elevation of GFAP
returned toward normal with longer durations of diabetes
(12 months). Feit-Leichman et al49 concluded that although
diabetes transiently activated apoptotic signaling in a small
population of neurons in the mouse retina, the damage was
probably not great enough to induce Müller gliosis in mice.
The classic RAS is indirectly involved in the pathogen-
esis of vascular diseases by many different mechanisms,
including modulation of immune cell function and/or
recruitment. Ang II activation of the p38emitogen-activated
protein kinaseedependent pathway promotes the production
of CCL2, a soluble chemotactic cytokine, in blood ves-
sels.30 Importantly, CCL2 is the most common chemokine
found to be elevated in serum and vitreous of patients withajp.amjpathol.org - The American Journal of Pathology
ACE2 Overexpression Reverses DRDR.50,51 The study by Hazra et al5 found that monocytes
expressing the CCL2 receptor (CCR2) are present in
increased numbers in the circulation and are found to accu-
mulate in the retina of streptozotocin-diabetic mice, impli-
cating the CCL2-CCR2 axis in the development of DR.
There are two distinct populations of monocyte-derived
cells in the mammalian retina. Perivascular macrophages are
situated among the inner retinal vasculature in the ganglion
cell layer, and the retinal microglia are located within the
inner plexiform layer and outer plexiform layer.52 Basal
levels of microglial activity are essential for maintaining
retinal homeostasis, including normal vascularization of the
retina.53 However, their hyperactivation is implicated in
the progression of many diseases, including DR.54 Hyper-
activation is characterized by the release of toxic molecules
(TNF-a, IL-1b, O2
, and nitric oxide) that are intended to
destroy offending pathogens.54,55 In fact, microglia are
considered the early primary source of IL-1 in central ner-
vous system injury, infection, and inﬂammation. IL-1b is a
trigger of the neuroinﬂammatory cascade,56 which (along
with TNF-a) increases caspase 3 activity, inducing endo-
thelial cell apoptosis,57,58 which could directly contribute to
the increase of acellular capillaries in DR (Figure 2). Acti-
vated microglia have also been proposed to stimulate a cycle
of inﬂammation that recruits leukocytes, causes vascular
damage, and directly induces glial dysfunction and neuronal
cell death through the release of cytotoxic substances.59
Thus, early destruction of the blood-retinal barrier in DR60
may be driven by glial hyperactivation.59 Exposure of
microglia to inﬂammatory agents (including advanced gly-
cation end products, TNF-a, IL-1, IL-6, interferon-g) results
in microglial activation and production of inﬂammatory
mediators (eg, TNF-a, IL-1, IL-6, IL-8, CCL2),61e63 func-
tioning in a paracrine and/or autocrine feed-forward loop to
further compromise the blood-retinal barrier and elevate
local retinal inﬂammation.54,61,64 Therefore, we propose that
the decline of microglial/macrophage cells in streptozotocin-
ACE2 is at least partly responsible for the prevention and
partial reversal of retinal vascular disease in the present
study (Figure 2).
In both the prevention and reversal studies, F4/80þ
macrophage/microglial cells located within the ganglion cell
layer of diabetic and nondiabetic animals were predomi-
nantly ameboid or elongated in appearance, consistent with
an activated phenotype. These cells were increased in
streptozotocin-control by approximately threefold to four-
fold compared with nondiabetic or ACE2-treated diabetic,
consistent with previous ﬁndings.65,66 Also consistent with
our ﬁndings (Figure 5), DR has generally been found to be
associated with increased microglia number near retinal
vasculature in the inner retinal layers and in the outer
plexiform layer,25,67 normally localizing anterior to the
outer nuclear layer.52 This organization within the ganglion
cell layer is consistent with the ﬁnding, in individuals with
DR, that microglia accumulate around regions of vascular
damage25 and that vascular lesions in the diabetic retina areThe American Journal of Pathology - ajp.amjpathol.orgnonuniform in distribution.20 However, microglia have also
been observed in the outer nuclear and photoreceptor layers
after 14 to 16 months of streptozotocin-induced diabetes,
presumably migrating to areas of neuronal damage.67 An
alternative possibility is that these cells are responsible for
the nonuniform pattern of vascular lesions that characterize
the diabetic retina.20 It is not possible to determine, in
this study, whether localized areas of macrophage hyper-
activation contribute to neurovascular damage or whether
macrophages migrate preferentially to areas of neurovascular
damage. However, the literature supports the concept that
macrophages and inﬂammatory cells play a major role in the
development of vascular alterations in diabetes.68,69
One possible mechanism whereby ACE2 overexpression
attenuates the diabetes-associated increase of macrophage/
microglial cells (Figure 5) is attributable to the ability of
Ang(1-7) to antagonize AGTR1s (which are expressed on
microglia). AGTR1 blockade with valsartan effectively
decreased microglial density in a rodent model of DR.70
Consistent with our ﬁndings, McVicar et al65 found a sig-
niﬁcant increase of F4/80þ microglia in the retina when
compared with nondiabetic controls, after 3 and 6 months
of diabetes in mice. Similarly, Muther et al71 observed a
regular distribution of F4/80þ in the healthy mouse retina.
Topics for Future Investigation
There are several interesting observations from this
study that remain only partially explained. Despite the
improvement of retinal vasculature in the diabetic AAV-
ACE2 animals, we still observed bone marrowederived,
perivascular cells, which possessed dendritic processes
and were labeled with F4/80. The question remains
whether up-regulation of the retinal vasoprotective RAS
induces a phenotypic shift in the macrophage/microglial
cells toward more anti-inﬂammatory cells. Another inter-
esting observation was that inﬁltrating bone marrow cells
localized to the diabetic retina in clusters, which begs the
question whether they are localizing to vascular/neural
injury or causing it. An important next step is to conﬁrm
these ﬁndings in a type 2 diabetes model because the
prevalence of type 2 is much greater than type 1 and
accounts for most DR cases. However, the type 1 studies
performed are justiﬁable because the incidence of type 1
diabetes is also increasing and the risk of DR in in-
dividuals with type 1 diabetes is greater than in those with
type 2 diabetes.72
Because the diabetic retina is strongly associated with
proinﬂammatory molecules, future studies should consider
the addition of an antioxidant to gene therapy to enhance
outcomes. For example, in the reversal study, the numbers
of acellular capillaries were only partially reversed, and
the increase in GFAP expression was not reversed by
vasoprotective RAS overexpression. It is possible that a
substantial proinﬂammatory stimulus remains, despite the
overexpression of protective mediators.1697
Dominguez et alConclusions
The ﬁndings of this study support the overall hypothesis that
by opposing the disproportionate increase of the local retinal
vasodeleterious RAS, key indices of DR can be prevented
and reversed in rodents with type 1 diabetes. Speciﬁcally,
AAV-mediated overexpression of retinal ACE2 decreased
the diabetes-associated increase of intracapillary bone
marrow cells, which we believe is at least partly responsible
for the improvement of retinal vascular disease in diabetic
animals. The use of GFPþ-chimeric mice allowed us to
distinguish inﬁltrating cells from resident cells and in
conjunction with immunohistochemistry allowed us to
conﬁrm a deleterious contribution of the cells from the
diabetic bone marrow. Accordingly, we observed an atten-
uation of glial/macrophage immunoreactivity in the diabetic
retina with our gene therapy approach, supporting the
contention that the overall inﬂammatory status of the retina
was improved. Thus, we propose that local retinal over-
expression of vasoprotective RAS successfully counters the
diabetes-associated elevation of vasodeleterious RAS,
which not only prevented but also reversed several charac-
teristics of long-standing DR, despite systemic hypergly-
cemia. These ﬁndings are very exciting because it has
traditionally been believed that acellular capillaries repre-
sent irreversible lesions. Collectively, the results of this set
of studies provide further support for the hypothesis that an
imbalance between the two axes of the RAS is a key initial
event that leads to development of diabetic microvascular
complications. The use of AAV-ACE2 via intravitreal
injection may represent a novel strategy for DR in humans
and should be considered as a possible therapeutic approach
for other microvascular and macrovascular complications of
diabetes.
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